Citadel Advisors
NEPH icon

Citadel Advisors’s Nephros NEPH Stock Holding History

Citadel Advisors’s Portfolio NEPH Stock Details NEPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$104K Buy
29,044
+8,156
+39% +$26.5K ﹤0.01% 12679
2026
Q1 		$62.2K Buy
20,888
+178
+0.9% +$711 ﹤0.01% 12312
2025
Q4 		$101K Buy
20,710
+4,165
+25% +$21.3K ﹤0.01% 11635
2025
Q3 		$78.3K Buy
16,545
+4,655
+39% +$18.3K ﹤0.01% 11987
2025
Q2 		$48.6K Sell
11,890
-134
-1% -$358 ﹤0.01% 11782
2025
Q1 		$20.7K Sell
12,024
-2,265
-16% -$3.55K ﹤0.01% 13120
2024
Q4 		$20.9K Sell
14,289
-2,947
-17% -$4.49K ﹤0.01% 13157
2024
Q3 		$29.5K Buy
17,236
+5,388
+45% +$10.7K ﹤0.01% 12457
2024
Q2 		$25K Buy
+11,848
New +$25.6K ﹤0.01% 12439
2023
Q2 		– Sell
-15,295
Closed -$16.7K – 14933
2023
Q1 		$16.7K Sell
15,295
-3,045
-17% -$3.5K ﹤0.01% 13191
2022
Q4 		$20.5K Buy
18,340
+5,225
+40% +$5.57K ﹤0.01% 13124
2022
Q3 		$12K Buy
13,115
+992
+8% +$1.4K ﹤0.01% 12230
2022
Q2 		$19K Buy
+12,123
New +$32.7K ﹤0.01% 12424
2021
Q2 		– Sell
-18,421
Closed -$123K – 14142
2021
Q1 		$123K Buy
+18,421
New +$145K ﹤0.01% 12269

Other funds holding NEPH

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
CC
Cornerstone Capital Palo Alto, California $1.12B AUM 28.84% 1-Year Est. Return
BA
Bard Associates Chicago, Illinois $451M AUM 66.6% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
MFIM
Mesirow Financial Investment Management Chicago, Illinois $6.37B AUM 23.22% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return
NA
Navellier & Associates Reno, Nevada $1.26B AUM 95.39% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Citadel Advisors's NEPH Position: Q2 2026 in Review

Citadel Advisors increased its Nephros (NEPH) stake by 39% in Q2 2026, buying an estimated $26.5K and bringing the position to 29,044 shares worth $104K. The position accounts for ﹤0.01% of the portfolio, ranked #12679.

Citadel Advisors first reported a position in NEPH in Q1 2021 and has held it in 14 quarters since. The position peaked at $123K in Q1 2021. 29 funds tracked by Wall St. Rank hold NEPH as of Q2 2026.

  • Citadel Advisors held 29,044 shares of Nephros worth $104K as of Q2 2026.
  • Citadel Advisors bought 8,156 Nephros shares in Q2 2026, an estimated $26.5K.
  • Nephros made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #12679 holding.
  • Citadel Advisors first reported a position in Nephros in Q1 2021 and has held it in 14 quarters since.
  • Citadel Advisors's Nephros position peaked at $123K in Q1 2021.
  • 29 funds tracked by Wall St. Rank held Nephros as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.